Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

1.050 +0.040 (+3.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nektar Therapeutics

< Previous 1 2 3 4 5 Next >
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. 
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024
NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Sweet Nektar?
NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around. 
Via Talk Markets
Nektar Therapeutics Earnings Preview
Via Benzinga
Recap: Nektar Therapeutics Q3 Earnings
Via Benzinga
A Preview Of Nektar Therapeutics's Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair... 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Earnings Scheduled For March 4, 2024
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Expert Ratings for Nektar Therapeutics
Via Benzinga
Nektar Therapeutics: Q1 Earnings Insights
Via Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The One-Minute Market Report - Saturday, Aug. 12
In this weekly outlook, I examine the asset classes, sectors, and ETFs that led the market higher, and which market segments bucked the trend by moving lower. Signs that market participation is... 
Via Talk Markets
Topics ETFs
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Nektar Therapeutics Stock Surging Today?
Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented "erroneous data" from two Phase 1b studies of its atopic dermatitis drug,  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Tempur Sealy International, Inc. (NYSE: TPX) from $48 to $50. Keybanc analyst Bradley Thomas maintained an Overweight rating. Tempur Sealy International shares rose... 
Via Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
This month, H.C. Wainwright & Co. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.